As of 2026-03-10, the EV/EBITDA ratio of Vir Biotechnology Inc (VIR) is -1.72. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. VIR's latest enterprise value is 807.15 mil USD. VIR's TTM EBITDA according to its financial statements is -468.24 mil USD. Dividing these 2 quantities gives us the above VIR EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 9.2x - 13.4x | 10.9x |
| Forward P/E multiples | 7.5x - 13.1x | 9.6x |
| Fair Price | (38.43) - (55.65) | (43.07) |
| Upside | -492.1% - -667.8% | -539.4% |
| Date | EV/EBITDA |
| 2026-03-06 | -1.67 |
| 2026-03-05 | -1.57 |
| 2026-03-04 | -1.67 |
| 2026-03-03 | -1.52 |
| 2026-03-02 | -1.62 |
| 2026-02-27 | -1.56 |
| 2026-02-26 | -1.62 |
| 2026-02-25 | -1.77 |
| 2026-02-24 | -1.65 |
| 2026-02-23 | -1.19 |
| 2026-02-20 | -1.22 |
| 2026-02-19 | -1.28 |
| 2026-02-18 | -1.28 |
| 2026-02-17 | -1.20 |
| 2026-02-13 | -1.20 |
| 2026-02-12 | -1.25 |
| 2026-02-11 | -1.18 |
| 2026-02-10 | -1.21 |
| 2026-02-09 | -1.15 |
| 2026-02-06 | -1.13 |
| 2026-02-05 | -1.07 |
| 2026-02-04 | -1.20 |
| 2026-02-03 | -1.24 |
| 2026-02-02 | -1.25 |
| 2026-01-30 | -1.19 |
| 2026-01-29 | -1.27 |
| 2026-01-28 | -1.22 |
| 2026-01-27 | -1.25 |
| 2026-01-26 | -1.19 |
| 2026-01-23 | -1.22 |
| 2026-01-22 | -1.18 |
| 2026-01-21 | -1.08 |
| 2026-01-20 | -0.86 |
| 2026-01-16 | -0.88 |
| 2026-01-15 | -0.91 |
| 2026-01-14 | -1.05 |
| 2026-01-13 | -0.93 |
| 2026-01-12 | -0.84 |
| 2026-01-09 | -0.83 |
| 2026-01-08 | -0.85 |
| 2026-01-07 | -0.90 |
| 2026-01-06 | -0.85 |
| 2026-01-05 | -0.82 |
| 2026-01-02 | -0.85 |
| 2025-12-31 | -0.87 |
| 2025-12-30 | -0.83 |
| 2025-12-29 | -0.86 |
| 2025-12-26 | -0.86 |
| 2025-12-24 | -0.89 |
| 2025-12-23 | -0.86 |